The True Annual Cost of Tirzepatide: Commitment Math Explained
Released · Last reviewed
A 12-month tirzepatide prepay lowers the monthly rate but locks you in; month-to-month costs more but lets you stop. The right choice depends on tolerability certainty and cancellation exposure.
- 12-month prepay lowers the rate but binds you to a non-FDA-approved product for a year.
- Month-to-month costs more per month but preserves the ability to stop without a balance.
- Prepaid plans commonly refuse refunds on medication already dispensed.
- Start short-term to confirm tolerability before committing to a long plan.
How commitment tiers work
Nearly every tirzepatide program lowers the monthly rate as the commitment lengthens. A 12-month prepay might drop the rate by $50 or more per month versus month-to-month. The discount is real, but so is the lock-in: you are prepaying for a year of a compounded, non-FDA-approved medication.
The saving from a longer commitment is only worth it if you are confident you will stay on the medication. If a side effect forces you off in month two, the remaining ten months are often non-refundable.
The annual math
Consider a program at $199 month-to-month versus $149 on a 12-month prepay. Month-to-month for a year is $2,388; the prepay is $1,788 — a $600 saving. But the prepay is paid upfront and rarely refundable. If you stop after three months, you have paid $1,788 for three months of use, an effective $596 per month.
This is the trap of commitment pricing: the advertised low rate assumes you complete the full term. Model both the best case (you finish) and the worst case (you stop early) before committing.
| Plan | Monthly | Annual | Refundable? |
|---|---|---|---|
| Month-to-month | $199 | $2,388 | Stop anytime |
| 6-month | $179 | $2,148 (prepaid) | Usually no |
| 12-month | $149 | $1,788 (prepaid) | Usually no |
Cancellation exposure
Prepaid and committed plans are subject to the governing agreement and typically require written notice, often 30 days, during which billing may continue. Medication already dispensed generally cannot be returned or refunded. This means your true exposure on a committed plan is the full prepaid amount plus any notice-period charges.
Read the cancellation terms before enrolling, not after. A program that makes cancellation easy and refunds undelivered months is lower-risk than one that locks the full year regardless of whether you continue.
| Plan | Paid | Months used | Effective/mo |
|---|---|---|---|
| Month-to-month | $597 | 3 | $199 |
| 12-month prepay | $1,788 | 3 | $596 |
The defensible strategy
For a first-time tirzepatide patient, the defensible approach is to start month-to-month or on the shortest available tier, confirm tolerability and supply reliability, and only then convert to a longer commitment. The extra cost of month-to-month for the first few months is cheap insurance against being locked into a year of a medication you cannot tolerate.
The savings from a 12-month prepay are not worth carrying if a side effect ends treatment in month two with no refund. Weigh the per-month discount against the cost of being wrong about a year-long commitment.
Frequently asked questions
Is a 12-month tirzepatide plan worth it?
Only if you are confident you will complete it. The discount is real, but prepaid plans are usually non-refundable, so stopping early can cost far more per month than month-to-month.
Can I get a refund if I stop?
Usually not on medication already dispensed. Committed plans typically require written notice and may bill through the notice period. Read the terms first.
What is the safest approach?
Start month-to-month or short-term, confirm you tolerate the medication, then commit to a longer plan for the discount.
Sources
- FDA — human drug compounding and GLP-1 status.
- Provider plan terms captured September 2026.
- Evidence ledger: evidence-ledger.csv.
The numbers behind this page
The tirzepatide price range, stated precisely
Standard-dose compounded tirzepatide runs $86 to $299 a month across the 24 programmes we priced on October 15, 2026, with a median of $144. The spread is $213 a month, or $2,556 across a year, for a molecule that is chemically identical in every case.
The lowest standing month-to-month prices with no membership are Mondae at $126 and Eden at $129; lower stickers come with a sale, a prepaid term or a membership. Half the programmes sit below $144 and half above it, which makes the median a more useful reference point than the lowest sticker when judging a quote.
Four programmes printed a tirzepatide microdose price on October 15, 2026, from $116 (Telos RX, "as low as") to $199 (Shed). Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Three questions to ask before acting on tirzepatide
On October 15, 2026, compounded tirzepatide ran $86 to $299 a month across the 24 programmes we priced.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Standard-dose tirzepatide spans $86 to $299 a month across the 24 programmes we priced on October 15, 2026, a spread of $213.
At the October 15, 2026 semaglutide median of $99 a month, medication alone runs $1,188 a year, $3,564 over three and $5,940 over five. At $279, the highest all-in rate we read, the same horizons are $3,348, $10,044 and $16,740.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What does compounded tirzepatide normally cost?
$86 to $299 a month at the lowest all-in rate across the 24 programs we priced on October 15, 2026, with a median of $144. Half the programs sit either side of that median, which makes it a better reference than the lowest sticker when you judge a quote.
Does compounded tirzepatide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed tirzepatide cheaper?
Because it is less medicine. On October 15, 2026, four programs printed a tirzepatide microdose price, from $116 (Telos RX, "as low as") to $199 (Shed); NexLife's microdose plan was $189 month-to-month or $147 a month on 12 months; since November 8, 2026 it is $129 or $115, the same as the standard plan. A microdose sits below every dose studied in the pivotal trials.
What does compounded tirzepatide cost per month in October 2026?
As of October 15, 2026, the 24 compounded tirzepatide programs we could price on their own pages charge between $86 and $299 a month at their lowest all-in rate, with a median of $144, counting any required membership and the cheapest plan term each program prints. The $86 figure is Collective's $69 monthly price plus its $199 annual membership spread over twelve months. Standing month-to-month rates with no membership start at $126 (Mondae) and $129 (Eden); as of November 6, 2026, NexLife is $129 month-to-month and $115 on a 12-month plan. Compounded tirzepatide is not FDA-approved.